However, immunohistochemical analyses reveal a more substantial impact at the protein level: 25.8% of primary CRC tumors lacked ARID1A expression, and 51.2% showed low expression, resulting in 77% of all CRC samples exhibiting absent or reduced ARID1A levels [4]. The gene discussed is ARID1A; the disease is colorectal carcinoma.